{"id":"NCT01098539","sponsor":"GlaxoSmithKline","briefTitle":"A Study of the Efficacy and Safety of Albiglutide in Subjects With Type 2 Diabetes With Renal Impairment.","officialTitle":"A Randomized, Double-Blind, Active-Controlled, Parallel-Group, Multicenter Study to Determine the Efficacy and Safety of Albiglutide as Compared With Sitagliptin in Subjects With Type 2 Diabetes Mellitus With Renal Impairment","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2010-05","primaryCompletion":"2012-11","completion":"2012-11","firstPosted":"2010-04-02","resultsPosted":"2014-05-16","lastUpdate":"2017-02-28"},"enrollment":507,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Diabetes Mellitus, Type 2"],"interventions":[{"type":"BIOLOGICAL","name":"albiglutide","otherNames":[]},{"type":"DRUG","name":"sitagliptin","otherNames":[]}],"arms":[{"label":"albiglutide","type":"ACTIVE_COMPARATOR"},{"label":"sitagliptin","type":"ACTIVE_COMPARATOR"}],"summary":"This randomized, double-blind, active-controlled study evaluates the efficacy and safety of a weekly dose of albiglutide as compared with sitagliptin. Subjects who are renally impaired with a historical diagnosis of type 2 diabetes mellitus and whose glycemia is inadequately controlled on their current regimen of diet and exercise or their antidiabetic therapy of metformin, thiazolidinedione, sulfonylurea, or any combination of these oral antidiabetic medications will be recruited into the study.","primaryOutcome":{"measure":"Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 26","timeFrame":"Baseline; Week 26","effectByArm":[{"arm":"Albiglutide 30 mg","deltaMin":-0.83,"sd":0.062},{"arm":"Sitagliptin 100 mg","deltaMin":-0.52,"sd":0.063}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.0001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":10},"locations":{"siteCount":218,"countries":["United States","Australia","Brazil","Colombia","Germany","India","Israel","Peru","Philippines","Russia","South Africa","South Korea","Spain","Taiwan","United Kingdom"]},"refs":{"pmids":["39963952","25387217"],"seeAlso":["https://www.clinicalstudydatarequest.com"]},"adverseEventsSummary":{"seriousAny":{"events":30,"n":249},"commonTop":["Hypoglycaemia","Urinary tract infection","Diarrhoea","Upper respiratory tract infection","Nasopharyngitis"]}}